Fenwick represented Freenome, a privately held biotechnology company, in its $300million Series D financing. The round was led by investors Perceptive Advisors and RA Capital Management and existing investors including a16z Life Sciences Growth Fund, the American Cancer Society’s BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company LLC, GV, Janus Henderson Investors, Kaiser Permanente, Novartis, Polaris Partners, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, with funds and accounts advised by T. Rowe Price Associates, Inc.
The funding will support the advancement of the company’s colorectal cancer (CRC) screening test and expansion of its multiomics platform to other cancers. More information can be obtained from Freenome’s announcement.
The Fenwick transaction team included corporate partners Michael Esquivel and Patrick Grilli, and associates Caroline Wells, Rich Minice, R. Harrison Dilday, Ethan Mackay and Brandon Ho; and regulatory partner Steve Albertson.